Daniel A Vallera

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. Vallera D, Chen H, Sicheneder A, Panoskaltsis Mortari A, Taras E. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res. 2009;33:1233-42 pubmed publisher
    ..DT2219ARL represents a new class of bispecific biological that can be continually improved by genetic mutation. ..
  2. Schmohl J, Todhunter D, Taras E, Bachanova V, Vallera D. Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies. Toxins (Basel). 2018;10: pubmed publisher
    ....
  3. Oh S, Ohlfest J, Todhunter D, Vallera V, Hall W, Chen H, et al. Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. J Neurooncol. 2009;95:331-342 pubmed publisher
    ..Thus, DTEGF13 is safe and efficacious as an alternative drug for glioblastoma therapy and warrants further study...
  4. Vallera D, Oh S, Chen H, Shu Y, Frankel A. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther. 2010;9:1872-83 pubmed publisher
    ..Because 2219KDEL7mut immunogenicity was significantly reduced and the drug was highly effective in vivo, we can now give multiple drug treatments with targeted toxins in future clinical trials. ..
  5. Schmohl J, Gleason M, Dougherty P, Miller J, Vallera D. Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells. Target Oncol. 2016;11:353-61 pubmed publisher
    ....
  6. Vallera D, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl J, et al. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clin Cancer Res. 2016;22:3440-50 pubmed publisher
    ..These qualities are ideal for NK cell therapy of myeloid malignancies or targeting antigens of solid tumors. Clin Cancer Res; 22(14); 3440-50. ©2016 AACRSee related commentary by Talmadge, p. 3419. ..
  7. Schmohl J, Vallera D. CD133, Selectively Targeting the Root of Cancer. Toxins (Basel). 2016;8: pubmed publisher
    ..In this review, we discuss the development and current status of these CD133 associated biological agents. Together, they show exceptional promise by specific and efficient CSC elimination. ..

Locale

Detail Information

Publications7

  1. Vallera D, Chen H, Sicheneder A, Panoskaltsis Mortari A, Taras E. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res. 2009;33:1233-42 pubmed publisher
    ..DT2219ARL represents a new class of bispecific biological that can be continually improved by genetic mutation. ..
  2. Schmohl J, Todhunter D, Taras E, Bachanova V, Vallera D. Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies. Toxins (Basel). 2018;10: pubmed publisher
    ....
  3. Oh S, Ohlfest J, Todhunter D, Vallera V, Hall W, Chen H, et al. Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. J Neurooncol. 2009;95:331-342 pubmed publisher
    ..Thus, DTEGF13 is safe and efficacious as an alternative drug for glioblastoma therapy and warrants further study...
  4. Vallera D, Oh S, Chen H, Shu Y, Frankel A. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases. Mol Cancer Ther. 2010;9:1872-83 pubmed publisher
    ..Because 2219KDEL7mut immunogenicity was significantly reduced and the drug was highly effective in vivo, we can now give multiple drug treatments with targeted toxins in future clinical trials. ..
  5. Schmohl J, Gleason M, Dougherty P, Miller J, Vallera D. Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells. Target Oncol. 2016;11:353-61 pubmed publisher
    ....
  6. Vallera D, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl J, et al. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clin Cancer Res. 2016;22:3440-50 pubmed publisher
    ..These qualities are ideal for NK cell therapy of myeloid malignancies or targeting antigens of solid tumors. Clin Cancer Res; 22(14); 3440-50. ©2016 AACRSee related commentary by Talmadge, p. 3419. ..
  7. Schmohl J, Vallera D. CD133, Selectively Targeting the Root of Cancer. Toxins (Basel). 2016;8: pubmed publisher
    ..In this review, we discuss the development and current status of these CD133 associated biological agents. Together, they show exceptional promise by specific and efficient CSC elimination. ..